Research Paper Volume 10, Issue 9 pp 2394—2406

Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder

Figure 4. Rolipram increases level of phosphor-AMPK via CaMKKβ. (A-B) Time courses of the effects of db-cAMP and rolipram on phospho-AMPK levels in C2C12 cells. (C-D) Phospho-AMPK levels in cells treated with a PKA or CaMKKβ inhibitor. (E-F) Phospho-AMPK levels in cells treated with a SIRT1 inhibitor or expression SIRT6 siRNA.